✓ Editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Drug Reference

Mounjaro

Released: Last reviewed:

Brand name for tirzepatide, FDA-approved for type 2 diabetes mellitus.

By Eli Lilly
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.

Mounjaro overview

Brand name for tirzepatide, FDA-approved for type 2 diabetes mellitus.

Mounjaro at a glance

Manufacturer
Eli Lilly
FDA status
FDA-approved

Related pages

Key facts, checked November 20, 2026

Mounjaro and Zepbound are both tirzepatide from Lilly. The Mounjaro label (effective July 29, 2026) covers blood-sugar control in adults and children 10 and older with type 2 diabetes. The weight-management brand is Zepbound, whose Zepbound label covers adults with obesity or overweight and moderate to severe sleep apnea with obesity. In SURMOUNT-1 (NEJM 2022), tirzepatide 15 mg produced 20.9% average weight loss at 72 weeks (treatment-regimen estimand). Medicare’s GLP-1 Bridge covers the Zepbound KwikPen, not Mounjaro, per the Medicare.gov GLP-1 Bridge page.